High-dose ketoconazole for treatment of fungal infections of the central nervous system.
Mortality and complication rates remain unacceptably high with conventional intravenous and intrathecal therapy for patients with coccidioidal meningitis and intracerebral fungal lesions. We studied the ventricular and lumbar cerebrospinal fluid penetration of ketoconazole and the responses to therapy in two patients receiving ketoconazole orally, 800 mg daily, and amphotericin B intraventricularly for meningeal and extrameningeal coccidioidomycosis. Five patients received only 1200 mg of ketoconazole: one had uncomplicated coccidioidal meningitis, three had obstructive hydrocephalus due to coccidioidal meningitis, and one had a histoplasmal brain abscess. Ketoconazole concentrations in ventricular and lumbar fluid ranged from 0.05 to 1.65 micrograms/mL 4 and 8 hours after the dose. The mean penetration of ketoconazole (+/- SD) was 1.9% +/- 0.8% for ventricular fluid and 5.4% +/- 2.6% for lumbar fluid. Ketoconazole concentrations in cerebrospinal fluid varied directly with those in serum and with cerebrospinal fluid protein content. The encouraging clinical responses, convenience, safety, and the consistent penetration of ketoconazole into obstructed and nonobstructed cerebrospinal fluid support the use of these regimens as alternatives to conventional therapy.
D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000378:metabolism; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D003047:Coccidioidomycosis / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000378:metabolism; D007654:Ketoconazole; D010879:Piperazines / Q000008:administration & dosage* / Q000378:metabolism
D000935:Antifungal Agents; D007093:Imidazoles; D010879:Piperazines; D000666:Amphotericin B; D007654:Ketoconazole